跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-21AI 评分28

Eli Lilly 的 retatrutide 在睡眠呼吸暂停适应症上更接近上市

Lilly’s retatrutide creeps closer to market for sleep apnea

AI 导读

Eli Lilly 的三重激动剂 retatrutide 在睡眠呼吸暂停适应症上更接近上市。其肥胖适应症的上市预期为明年,公司也在推进该药用于睡眠呼吸暂停。

正文

Ex­pec­ta­tions for the launch of Eli Lil­ly’s triple ag­o­nist re­ta­tru­tide in obe­si­ty, due next year, are at fever pitch. But the com­pa­ny is al­so lin­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news